But Dr. Steve Finkbeiner and colleagues at the University of California in San Francisco and the university's Gladstone Institute of Neurological Disease have discovered that the mutant protein that clumps inside the brain cells of Huntington's patients actually saves cells from dying.
Amgen's decision reverberated beyond the 48 patients in the trials because the drug, called glial cell line-derived neurotrophic factor, or GDNF, had the potential to stall or even reverse the progression of the disease rather than just reduce the symptoms, as the currently available Parkinson's drugs do.
